Vaxart/ US92243A2006 /
2024-04-30 9:59:20 PM | Chg. +0.01 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.72USD | +0.81% | 12,421 Turnover: 8,683.72 |
-Bid Size: - | -Ask Size: - | 0.74 | 0.68 |
GlobeNewswire
04-30
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
GlobeNewswire
03-07
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
GlobeNewswire
03-06
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
GlobeNewswire
02-05
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Nex...
GlobeNewswire
01-19
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Eva...
GlobeNewswire
01-16
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
GlobeNewswire
2023-12-21
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating...
GlobeNewswire
2023-11-02
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire
2023-11-02
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
GlobeNewswire
2023-10-26
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November ...
GlobeNewswire
2023-09-21
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
GlobeNewswire
2023-09-06
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine C...
GlobeNewswire
2022-02-24
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire
2021-12-16
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron
GlobeNewswire
2021-11-23
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021